Taku Ito-Kureha

Taku Ito-Kureha

Auto-generated profile, based on publicly available information

Taku Ito-Kureha

Department of Immunology, Graduate School of Medicine and Faculty of Medicine, The University of Tokyo, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2022 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
TITaku Ito-Kureha
Taku Ito-Kureha
CLCristina Leoni
Cristina Leoni
KBKayla Borland
Kayla Borland
GCGiulia Cantini
Giulia Cantini
MBMarian Bataclan
Marian Bataclan
VHVigo Heissmeyer
Vigo Heissmeyer

29 June 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
CLCristina Leoni
Cristina Leoni
MBMarian Bataclan
Marian Bataclan
TITaku Ito-Kureha
Taku Ito-Kureha
VHVigo Heissmeyer
Vigo Heissmeyer
SMSilvia Monticelli
Silvia Monticelli
Mast cells are central players in allergy and asthma, and their dysregulated responses lead to reduced quality of life and life-threatening conditions such as anaphylaxis. The RNA modification N6-methyladenosine (m6A) has a prominent impact on immune cell functions, but its role in mast cells remains unexplored. Here, by optimizing tools to genetically manipulate primary mast cells, we reveal that the m6A mRNA methyltransferase complex modulates mast cell proliferation and survival. Depletion of the catalytic component Mettl3 exacerbates effector functions in response to IgE and antigen complexes, both in vitro and in vivo. Mechanistically, deletion of Mettl3 or Mettl14, another component of the methyltransferase complex, lead to the enhanced expression of inflammatory cytokines. By focusing on one of the most affected mRNAs, namely the one encoding the cytokine IL-13, we find that it is methylated in activated mast cells, and that Mettl3 affects its transcript stability in an enzymatic activity-dependent manner, requiring consensus m6A sites in the Il13 3’-untranslated region. Overall, we reveal that the m6A machinery is essential in mast cells to sustain growth and to restrain inflammatory responses.

11 March 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
MXMeng Xu
Meng Xu
TITaku Ito-Kureha
Taku Ito-Kureha
HKHyun-Seo Kang
Hyun-Seo Kang
ACAleksandar Chernev
Aleksandar Chernev
TRTimsse Raj
Timsse Raj
VHVigo Heissmeyer
Vigo Heissmeyer
The regulation of thymocyte development by RNA-binding proteins (RBPs) is largely unexplored. We identify 642 RBPs in the thymus and focus on Arpp21, which shows selective and dynamic expression in early thymocytes. Arpp21 is downregulated in response to T cell receptor (TCR) and Ca2+ signals. Downregulation requires Stim1/Stim2 and CaMK4 expression and involves Arpp21 protein phosphorylation, polyubiquitination and proteasomal degradation. Arpp21 directly binds RNA through its R3H domain, with a preference for uridine-rich motifs, promoting the expression of target mRNAs. Analysis of the Arpp21–bound transcriptome reveals strong interactions with the Rag1 3′-UTR. Arpp21–deficient thymocytes show reduced Rag1 expression, delayed TCR rearrangement and a less diverse TCR repertoire. This phenotype is recapitulated in Rag1 3′-UTR mutant mice harboring a deletion of the Arpp21 response region. These findings show how thymocyte-specific Arpp21 promotes Rag1 expression to enable TCR repertoire diversity until signals from the TCR terminate Arpp21 and Rag1 activities.

1 April 2025 in Cancer Gene Therapy
Verified
Journal Article
Open access
PDF file
MTMiho Tokumasu
Miho Tokumasu
ASAtsuko Sato
Atsuko Sato
TITaku Ito-Kureha
Taku Ito-Kureha
MYMizuki Yamamoto
Mizuki Yamamoto
NONao Ohmine
Nao Ohmine
TYTadashi Yamamoto
Tadashi Yamamoto
NF-κB mediates transcriptional regulation crucial to many biological functions, and elevated NF-κB activity leads to autoimmune and inflammatory diseases, as well as cancer. Since highly aggressive breast cancers have few therapeutic molecular targets, clarification of key molecular mechanisms of NF-κB signaling would facilitate the development of more effective therapy. In this report, we show that Tob, a member of the Tob/BTG family of antiproliferative proteins, acts as a negative regulator of the NF-κB signal in breast cancer. Studies with 35 human breast cancer cell lines reveal that Tob expression is negatively correlated with NF-κB activity. Analysis of The Cancer Genome Atlas (TCGA) database of clinical samples reveals an inverse correlation between Tob expression and NF-κB activity. Tob knockdown in human breast cancer cells promoted overactivation of NF-κB upon TNF-α treatment, whereas overexpression of Tob inhibited TNF-α stimulation-dependent NF-κB activation. Mechanistically, Tob associates with the TNF receptor complex I and consequently inhibits RIPK1 polyubiquitylation, leading to possible prevention of overwhelming activation of NF-κB.

17 July 2026 in Science Advances
Verified
Journal Article
Open access
RMRyunosuke Muro
Ryunosuke Muro
SWSuqi Wang
Suqi Wang
TITaku Ito-Kureha
Taku Ito-Kureha
HHHung Hiep Huynh
Hung Hiep Huynh
KKKouji Kobiyama
Kouji Kobiyama
HTHiroshi Takayanagi
Hiroshi Takayanagi
Lipid nanoparticle–encapsulated mRNA (mRNA-LNP) vaccines trigger the potent differentiation of antigen-specific cytotoxic CD8 T cells in addition to antibody production. Despite its high immunogenicity, the cellular mechanisms by which mRNA-LNP induces such unusual immune responses remain largely unclear. Here, we show that mRNA-LNP induces potent and long-lasting CD8 T cell expansion through an antigen presentation mechanism that differs from that of conventional adjuvants. In mice immunized with mRNA-LNP, the number of antigen-specific CD8 T cells was one order of magnitude higher than that induced by combining antigen proteins with immunostimulants such as lipopolysaccharide or polyinosinic:polycytidinic acid. Intramuscularly administered mRNA-LNPs were mainly taken up by migratory type 2 conventional dendritic cells in draining lymph nodes, resulting in notably strong and persistent antigen presentation through major histocompatibility complex class I. Furthermore, CD8 T cell induction by mRNA-LNP required migratory dendritic cells but not the traditional cross-presentation pathway that is otherwise essential for antiviral and antitumor immunity. Thus, the mRNA-LNP formulation exerts unconventional immune responses through a different antigen-presentation pathway from conventional component vaccines.

16 November 2021 in Research Square
Verified
Preprint
Open access
PDF file
TITaku Ito-Kureha
Taku Ito-Kureha
CLCristina Leoni
Cristina Leoni
KBKayla Borland
Kayla Borland
MBMarian Bataclan
Marian Bataclan
RMRebecca Metzger
Rebecca Metzger
VHVigo Heissmeyer
Vigo Heissmeyer
T cell antigen receptor (TCR) signaling controls the development, activation and survival of T cells by involving several layers and numerous mechanisms of gene regulation. N6-methyladenosine (m6A) is the most prevalent mRNA modification affecting splicing, translation and stability of transcripts. Here, we describe the Wtap protein as essential for m6A methyltransferase complex function and reveal its crucial role in TCR signaling. Wtap and m6A methyltransferase functions were required for the differentiation of thymocytes, control of activation-induced death of peripheral T cells and prevention of colitis by enabling gut RORγt+ regulatory T cell function. Transcriptome and epitranscriptomic analyses reveal that m6A modification destabilizes Orai1 and Ripk1 mRNAs. Lack of post-transcriptional repression of the encoded proteins correlated with increased store-operated calcium entry (SOCE) activity and diminished survival of T cells. These findings uncover how m6A modification impacts on TCR signal transduction and determines activation and survival of T cells.